Krystal Biotech (KRYS) Long-Term Deferred Tax (2025 - 2026)
Krystal Biotech (KRYS) posted quarterly Long-Term Deferred Tax of $22.8 million for Q2 2026, little changed on a QoQ basis from $22.8 million in Q1 2026.
Powered by 
Analysis
Krystal Biotech (KRYS) Long-Term Deferred Tax (2025 - 2026) Analysis & Trends
Krystal Biotech has reported Long-Term Deferred Tax for 2 years, with the latest figure at $22.8 million in Q2 2026.
- Long-Term Deferred Tax for Q2 2026 came in at $22.8 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2026 was $22.8 million (changed N/A YoY), and the FY2025 annual result was $22.8 million, changed N/A from the prior year.
- Long-Term Deferred Tax held at $22.8 million in Q2 2026, from $22.8 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $24.7 million in Q3 2025 and troughed at $22.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Krystal Biotech | 10.61 Bn | 9.76 Bn | 112.79 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22.82 Mn |
| Mar 31, 2026 | 22.82 Mn |
| Dec 31, 2025 | 22.82 Mn |
| Sep 30, 2025 | 24.68 Mn |